Proyectos de ley › 88.ª Asamblea General

HF 2253Murió al terminar la sesión · 19 de febrero de 2020

Relating to price transparency for prescription drugs sold in this state, and including applicability provisions

Temas:Business & economyHealth care

La misma legislación: HF 2551

Dónde está ahora

  1. Hecho: Presentado5 de febrero de 2020
  2. Hecho: Subcomité6 de febrero de 2020
  3. Hecho: Comité de la Cámara19 de febrero de 2020
  4. Se detuvo: Lo aprueba la CámaraMurió al terminar la Asamblea General
  5. Sigue: Comité del Senado
  6. Sigue: Lo aprueba el Senado
  7. Sigue: A gobernador(a)
  8. Sigue: Firmado como ley

Murió al terminar la sesión La sesión de 2020 terminó el 14 de junio de 2020, la última sesión ordinaria de la Asamblea General. Los proyectos que no pasaron por ambas cámaras murieron. ¿Qué es el embudo (funnel)?

Qué contiene

La explicación oficial está en inglés; todavía no hay resumen en palabras sencillas.

This bill relates to price transparency for prescription drugs sold in this state. The bill requires a manufacturer to file an annual report with the commissioner of insurance (commissioner) that discloses the wholesale acquisition cost for all prescription drugs manufactured by the manufacturer that were sold to a person in this state in the immediately preceding calendar year. “Wholesale acquisition cost” or “cost” is defined in the bill as the manufacturer’s list price for a prescription drug for wholesalers or direct purchasers in the United States, not including prompt pay or other discounts, rebates, or reductions in price, for the most recent month for which the information is available, as reported in wholesale price guides or other publications of drug or biological pricing data.

Lea la explicación completa

Within calendar days of receipt, the commissioner is required to publish this information from the annual reports on a publicly accessible internet site. If a prescription drug sold to a person in this state has a cost of $100 or more for a 30-day supply and the cost increases percent or more over three consecutive calendar years, or increases percent or more in a single calendar year, the manufacturer of the prescription drug must file a report with the commissioner within calendar days of the date on which the or percent increase in cost occurs. This requirement is applicable to all manufacturers that manufactured prescription drugs that are sold to a person in this state on or after January 1, 2021. The report must include the information detailed in the bill. Certain information provided by a manufacturer, as detailed in the bill, is considered a confidential record and is required to be protected as a trade secret. Within calendar days of receipt, the commissioner is required to publish the nonconfidential information on the same publicly accessible internet site on which the manufacturer’s annual report information is published. The bill requires each health carrier to submit an annual report by February to the commissioner that contains information as detailed in the bill across all of the health carrier’s health benefit plans. This requirement is applicable to all health benefit plans providing for third-party payment or prepayment of health or medical expenses that provide a prescription drug benefit that have been delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2021. “Health carrier” is defined in the bill as an entity subject to the insurance laws and regulations of this state, or subject to the jurisdiction of the commissioner, including an insurance company offering sickness and accident plans, a health maintenance organization, a nonprofit health service corporation, a plan established pursuant to Code chapter 509A for public employees, or any other entity providing a plan of health insurance, health care benefits, or health care services. Certain information provided by a health carrier, as detailed in the bill, is considered a confidential record and must be protected as a trade secret. Prior to May of each year, the commissioner must publish the nonconfidential data received by the commissioner on the same publicly accessible internet site on which the manufacturers’ information is published. The data must be aggregated from the annual reports submitted by all health carriers. The bill directs the commissioner to adopt rules as necessary to administer the requirements outlined in the bill and allows the commissioner to take any action within the commissioner’s authority to enforce compliance with the requirements outlined in the bill.

Texto completo del proyecto (en inglés)1

House subcommittee

Named February 6, 2020. On February 12, 2020 it recommended passage.

Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part

Nota fiscal

Resumen con IA This bill requires prescription drug manufacturers and health carriers to file annual reports regarding drug costs and health benefit plans. The state's Commerce Revolving Fund would pay an estimated $171,000 annually to fund two new full-time positions to oversee these requirements. The costs and potential revenue from enforcement actions are difficult to estimate. (en inglés)2

Lea la nota fiscal (en inglés)

Description

House File 2551 does the following:

  • Requires prescription drug manufacturers to file an annual report with the Insurance Division Commissioner that discloses the wholesale acquisition cost for each prescription drug manufactured by the manufacturer that was sold in the State in the previous calendar year.
  • Requires prescription drug manufacturers to file a special report for prescription drugs meeting certain price amounts as specified in the Bill.
  • Requires health carriers to submit an annual report by February 1 of each year regarding health benefit plans that offer a prescription drug benefit.

Additionally, the Bill provides enforcement authority to allow the Insurance Division to take action in cases of failure to comply with the requirements of the Bill.

Background

The Insurance Division does not have regulatory authority over prescription drug manufacturers; however, the Division became involved in the practice of requiring disclosures regarding drug pricing methodology in 2014. In 2017, a 2014 amendment to Iowa Code chapter 501B was subject to litigation in Pharmaceutical Care Management Association (PCMA) v. Gerhart, which resulted in a U.S. Court of Appeals Eighth Circuit decision that the federal Employee Retirement Income Security Act of 1974 (ERISA) expressly preempts Iowa Code section 510B.8. Iowa Code section 510B.8 regulated how pharmacy benefits managers set drug prices and required certain disclosures. Pharmacy benefits managers are health care entities that contract with insurers, employers, unions, and government programs to administer the prescription drug portion of a health care benefit.

Assumptions

The Division estimates that a minimum of 2.0 full-time equivalent (FTE) positions at the Insurance Company Examiner Specialist 2 and Compliance Officer 1 classifications would be needed to perform the duties specified in the Bill. The 2.0 FTE positions would be assigned to review and examine the reports filed to verify that the reports are in compliance.

Fiscal Impact

The resources required to implement the enforcement authority component of the Bill are difficult to estimate, as is the potential revenue generated from fines assessed under the provisions of the Bill. However, the 2.0 FTE positions at the Insurance Company Examiner Specialist 2 and Compliance Officer 1 classifications would result in an annual estimated cost of $171,000. Any appropriation for additional staff would be from the Commerce Revolving Fund.

Source

  • Iowa Insurance Division

Cómo leer una nota fiscal3

Lo que cambia del Código de Iowa (Iowa Code)

Crea§510D.1§510D.2§510D.3§510D.4§510D.5§510E.1§510E.2§510E.3§510E.4

Cómo funciona el Código4

Cabildeo

8 a favor · 8 en contra · 21 indecisos · Quiénes →

Family tree

Earlier and later bills are matched by wording or an identical title.

Similar bills

  • HF 464 Relating to price transparency and cost-sharing for prescription drugs, and including appl…
    89th General Assembly · In committee
    Nearly identical
  • HSB 46 HSB 46
    89th General Assembly · Approved by committee
    Very similar

Matched by wording or an identical title.